Dosing characteristics of oral treprostinil in real-world clinical practice

Pharmacokinetic studies with oral treprostinil demonstrate that three times daily (TID) dosing reduces peak-to-trough plasma trepostinil fluctuations compared with twice daily (BID) dosing. TID dosing may allow for faster titration, higher total daily doses, and potentially improve the tolerability...

Descripción completa

Detalles Bibliográficos
Autores principales: Balasubramanian, Vijay P., Messick, Chad R., Broderick, Meredith, Nelsen, Andrew C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055265/
https://www.ncbi.nlm.nih.gov/pubmed/29582710
http://dx.doi.org/10.1177/2045894018770654
_version_ 1783341139065044992
author Balasubramanian, Vijay P.
Messick, Chad R.
Broderick, Meredith
Nelsen, Andrew C.
author_facet Balasubramanian, Vijay P.
Messick, Chad R.
Broderick, Meredith
Nelsen, Andrew C.
author_sort Balasubramanian, Vijay P.
collection PubMed
description Pharmacokinetic studies with oral treprostinil demonstrate that three times daily (TID) dosing reduces peak-to-trough plasma trepostinil fluctuations compared with twice daily (BID) dosing. TID dosing may allow for faster titration, higher total daily doses, and potentially improve the tolerability of oral trepostinil. This analysis, which looks at the real-world dosing of oral treprostinil, supports the utility of TID dosing.
format Online
Article
Text
id pubmed-6055265
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-60552652018-07-25 Dosing characteristics of oral treprostinil in real-world clinical practice Balasubramanian, Vijay P. Messick, Chad R. Broderick, Meredith Nelsen, Andrew C. Pulm Circ Research Letter Pharmacokinetic studies with oral treprostinil demonstrate that three times daily (TID) dosing reduces peak-to-trough plasma trepostinil fluctuations compared with twice daily (BID) dosing. TID dosing may allow for faster titration, higher total daily doses, and potentially improve the tolerability of oral trepostinil. This analysis, which looks at the real-world dosing of oral treprostinil, supports the utility of TID dosing. SAGE Publications 2018-03-27 /pmc/articles/PMC6055265/ /pubmed/29582710 http://dx.doi.org/10.1177/2045894018770654 Text en © The Author(s) 2018 http://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Research Letter
Balasubramanian, Vijay P.
Messick, Chad R.
Broderick, Meredith
Nelsen, Andrew C.
Dosing characteristics of oral treprostinil in real-world clinical practice
title Dosing characteristics of oral treprostinil in real-world clinical practice
title_full Dosing characteristics of oral treprostinil in real-world clinical practice
title_fullStr Dosing characteristics of oral treprostinil in real-world clinical practice
title_full_unstemmed Dosing characteristics of oral treprostinil in real-world clinical practice
title_short Dosing characteristics of oral treprostinil in real-world clinical practice
title_sort dosing characteristics of oral treprostinil in real-world clinical practice
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055265/
https://www.ncbi.nlm.nih.gov/pubmed/29582710
http://dx.doi.org/10.1177/2045894018770654
work_keys_str_mv AT balasubramanianvijayp dosingcharacteristicsoforaltreprostinilinrealworldclinicalpractice
AT messickchadr dosingcharacteristicsoforaltreprostinilinrealworldclinicalpractice
AT broderickmeredith dosingcharacteristicsoforaltreprostinilinrealworldclinicalpractice
AT nelsenandrewc dosingcharacteristicsoforaltreprostinilinrealworldclinicalpractice

Ejemplares similares